Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;96(3):453-459.
doi: 10.1002/ana.27027. Epub 2024 Jul 4.

Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

Matthew R Brier  1   2 , Suzanne E Schindler  1 , Amber Salter  3 , Dana Perantie  1 , Nicole Shelley  1 , Bradley Judge  1 , Sarah Keefe  2 , Kristopher M Kirmess  4 , Philip B Verghese  4 , Kevin E Yarasheski  4 , Venky Venkatesh  4 , Cyrus A Raji  2 , Brian A Gordon  2 , Randall J Bateman  1 , John C Morris  1 , Robert T Naismith  1 , David M Holtzman  1 , Tammie L S Benzinger  2 , Anne H Cross  1
Affiliations

Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

Matthew R Brier et al. Ann Neurol. 2024 Sep.

Abstract

The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453-459.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest

Washington University in St. Louis holds equity in C2N Diagnostics and may receive royalties resulting from use of PrecivityAD2. MRB has no conflicts of interest. SES has analyzed data provided by C2N Diagnostics to Washington University. KK, PV, KY, and VV are employees of C2N Diagnostics. RJB has equity ownership interest in C2N Diagnostics and may receive income based on technology (stable isotope labeling kinetics, blood plasma assay, methods of diagnosing AD with phosphorylation changes, neurofilament light chain assays and materials) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. DMH is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies, U.S. patent no. 9,834,596. DMH cofounded, has equity, and is on the scientific advisory board of C2N Diagnostics. RTN, JCM, TLSB, and AHC have no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Hittle M, Culpepper WJ, Langer-Gould A, et al. Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA neurology. 2023; - PMC - PubMed
    1. Ostolaza A, Corroza J, Ayuso T. Multiple sclerosis and aging: comorbidity and treatment challenges. Multiple Sclerosis and Related Disorders. 2021/05/01/ 2021;50:102815. doi:10.1016/j.msard.2021.102815 - DOI - PubMed
    1. McDade EM. Alzheimer Disease. CONTINUUM: Lifelong Learning in Neurology. June 2022;28(3)doi:10.1212/CON.0000000000001131 - DOI - PubMed
    1. Hampel H, Hu Y, Cummings J, et al. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape. Neuron. Jun 5 2023;doi:10.1016/j.neuron.2023.05.017 - DOI - PMC - PubMed
    1. Schindler SE, Atri A. The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer’s disease diagnostic revolution. Nat Aging. May 2023;3(5):460–462. doi:10.1038/s43587-023-00400-6 - DOI - PMC - PubMed

LinkOut - more resources